FDA Approves Second CAR-T Therapy in US to Gilead’s Kite Pharma
By

By
The US Food and Drug Administration (FDA) has approved Yescarta (axicabtagene ciloleucel), a chimeric antigen receptor T cell (CAR-T) therapy, from Kite Pharma, a Santa Monica, California-headquartered cell therapy company…

Allergan Suffers Setback in Patent Litigation for Its Blockbuster Drug Restasis
By

By
A federal district court has ruled against Allergan in patent litigation for one of its top-selling drugs, Restasis (cyclosporine ophthalmic emulsion), a drug to treat dry eyes, and separately, Allergan…

Amneal Pharmaceuticals, Impax Laboratories To Merge
By

By
Amneal Pharmaceuticals, a Paterson, New Jersey-based generic-drug manufacturer, and Impax Laboratories, a Hayward, California-based specialty pharmaceutical company focused on controlled-release and specialty generics, have agreed to merge, to create what…

Friulchem Advances Conjugated Estrogens Project
By

By
Friulchem S.p.A., a Vivaro, Italy-based contract development, and manufacturing organization for innovator and generic pharmaceutical products for human and veterinary use, reports on a natural conjugated estrogen project. Friulchem S.p.A.…

Avantor Opens Korean Life-Sciences Research and Applications Facility
By

By
Avantor, a supplier of ultra-high-purity materials for the life-sciences and advanced technologies sectors, has opened a new life-sciences research and applications laboratory in GwangGyo district, Suwon, South Korea. The lab…

Nestlé Licenses Codexis’ Enzyme Platform
By

By
Nestlé Health Science, the healthcare nutrition business of the Nestlé Group, has agreed to license a protein engineering platform, CodeEvolver, from Codexis, a Redwood City, California-headquartered protein engineering and biocatalyst…

Sartorius Stedim Breaks Ground on Cell Culture Center
By

By
Sartorius Stedim Cellca, a Laupheim, Germany-based company specializing in mammalian cell-line and upstream process development, is building a new EUR 30-million ($35-million) Cell Culture Technology Center at Science Park III…

Batavia Biosciences Expands Viral Vector Facilities
By

By
Batavia Biosciences, a contract biologics manufacturer based in Leiden, the Netherlands, has expanded its viral vector process development facilities in the US and its GMP cleanroom facilities in the Netherlands.…

Cambrex Invests in API Manufacturing
By

By
Cambrex, a contract manufacturer of small-molecule active pharmaceutical ingredients (APIs), is investing in research and development and manufacturing capabilities for generic APIs, at its site in Paullo, Milan, Italy. The…

CordenPharma Invests in Small-Molecule Manufacturing
By

By
CordenPharma, a contract development and manufacturing organization of drug substances and drug products, is investing EUR 3.7 million ($4.3 million) in the manufacturing site infrastructure of its small-molecule manufacturing facility…